Areas of Activity

Contact us

15 October 2021

TransVaginal Female Sexual and SUI Treatment

The first of three already conducted clinical pilots, relate to using MoreNova for female Sexual Improvement and Stress Urinary Incontinence. The pilots presented at the International Continence Society (ICS) 2021 Melbourne conference.  

Treatment was offered to women suffering from stress urinary incontinence, sexual dysfunction or both conditions.  Initial results are highly encouraging.  Low intensity shockwaves promote angiogenesis, increase nitric oxide release (NO), induces release of vascular endothelial growth factor (VEGF), stimulates reproduction of stem cells and effects tissue regeneration.

Patented MoreNova applies low intensity shockwaves using patented applicators configured to deliver energy to anatomy of various shapes, i.e., linear, area and tubular.  The first ones allow external treatments while the latter allows internal vaginal treatments. Since low intensity shockwaves are painless and do not produce heat, concerns related to heat-related risk associated with other technologies are avoided.  Internal and external vaginal treatment allows for the ability to treat both improved sexual function as well as urinary incontinence and pain-related conditions.
The first pilot (ICS 2021) can be viewed at:
http://www.ics.org/2021/abstract/452 or https://lnked.in/eufPbS9J

About DirexGroup:
For over 35 years, DirexGroup has been promoting companies contributing to global Health and Wellness by introducing shockwaves and other devices with emphasis on simplicity, comfort and convenience.  Contact This email address is being protected from spambots. You need JavaScript enabled to view it.

About Hikkonu:
Hikkonu, promoted by DirexGroup, is focused on developing innovative and shockwaves-based devices for treating shallow and deep organs.
Hikkonu seeks investigators, distributors and partners.

Contact Us

© 2017 DirexGroup. All Rights Reserved.